000179298 001__ 179298
000179298 005__ 20240229145539.0
000179298 0247_ $$2doi$$a10.1080/10428194.2022.2053529
000179298 0247_ $$2pmid$$apmid:35343360
000179298 0247_ $$2ISSN$$a1026-8022
000179298 0247_ $$2ISSN$$a1029-2403
000179298 0247_ $$2ISSN$$a1042-8194
000179298 0247_ $$2altmetric$$aaltmetric:125521751
000179298 037__ $$aDKFZ-2022-00580
000179298 041__ $$aEnglish
000179298 082__ $$a610
000179298 1001_ $$0P:(DE-He78)3772dc9cbbc020fbc52b5f63f1dc1e96$$aPulte, Dianne$$b0$$eFirst author$$udkfz
000179298 245__ $$aIncidence and survival estimates for patients with myelodysplastic syndrome in the early 21st century: no evidence of improvement over time.
000179298 260__ $$aLondon [u.a.]$$bTaylor & Francis Group$$c2022
000179298 3367_ $$2DRIVER$$aarticle
000179298 3367_ $$2DataCite$$aOutput Types/Journal article
000179298 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1662031610_29854
000179298 3367_ $$2BibTeX$$aARTICLE
000179298 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000179298 3367_ $$00$$2EndNote$$aJournal Article
000179298 500__ $$a#EA:C070#LA:C070#LA:C120# / 2022 Aug;63(8):1964-1969
000179298 520__ $$aWe examine changes in population level incidence and survival of patients diagnosed with myelodysplastic syndrome (MDS) in the United States in 2001-2016. Data were extracted from the Surveillance, Epidemiology, and End Results (SEER)-18 database. Period analysis was used to calculate one-, two-, and five-year survival. The incidence peaked at 5.6 per 100,000 in 2010 then decreased to 3.9 by 2016, with a decrease in the diagnoses of refractory anemia (RA) and RA with ringed sideroblasts (RARS) and a relative increase in RA with excess blasts (RAEB). Overall, one-, two-, and five-year relative survival decreased over time, going from 74.3%, 60.9%, and 42.3%, respectively, in 2008-2010 to 70.9%, 55.9%, and 37.6%, respectively, in 2014-2016. When survival was examined by histology, patients with RA/RARS and RAEB had similar survival expectations in 2008-2010 versus 2014-2016 and a decrease was observed for 5q-MDS. Our results highlight the need for new treatment options in MDS.
000179298 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000179298 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000179298 650_7 $$2Other$$aMyelodysplastic syndromes
000179298 650_7 $$2Other$$aincidence
000179298 650_7 $$2Other$$aperiod analysis
000179298 650_7 $$2Other$$asurvival analysis
000179298 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b1$$udkfz
000179298 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b2$$eLast author$$udkfz
000179298 773__ $$0PERI:(DE-600)2030637-4$$a10.1080/10428194.2022.2053529$$gp. 1 - 6$$n8$$p1964-1969$$tLeukemia and lymphoma$$v63$$x1026-8022$$y2022
000179298 909CO $$ooai:inrepo02.dkfz.de:179298$$pVDB
000179298 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3772dc9cbbc020fbc52b5f63f1dc1e96$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000179298 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000179298 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000179298 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000179298 9141_ $$y2022
000179298 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-02-02$$wger
000179298 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLEUKEMIA LYMPHOMA : 2019$$d2021-02-02
000179298 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-02-02
000179298 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-02-02
000179298 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-02-02
000179298 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-02-02
000179298 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-02-02
000179298 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-02-02
000179298 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-02
000179298 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-02-02
000179298 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-02
000179298 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-02-02
000179298 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-02-02
000179298 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000179298 9202_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000179298 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000179298 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000179298 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000179298 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000179298 980__ $$ajournal
000179298 980__ $$aVDB
000179298 980__ $$aI:(DE-He78)C070-20160331
000179298 980__ $$aI:(DE-He78)C120-20160331
000179298 980__ $$aI:(DE-He78)HD01-20160331
000179298 980__ $$aUNRESTRICTED